Trump's CBD Post Boosts Pot Stocks as Reclassification Hopes Rise
U.S. President Donald Trump's recent social media post highlighting the potential benefits of cannabidiol (CBD) in senior healthcare has sparked a surge in shares of pot companies. This comes amidst ongoing discussions about the reclassification of marijuana, which could significantly impact the cannabis industry.
Trump's post has led to substantial gains in U.S.-listed shares of major cannabis companies such as Canopy Growth, Tilray Brands, Cronos Group, and Aurora Cannabis. This enthusiasm is further fueled by the potential role of cannabis in supporting health and wellness for seniors, as expressed by Canopy Growth.
The U.S. administration's recognition of cannabis and its potential benefits has also driven up exchange-traded funds by AdvisorShares and Roundhill, putting them on track for their biggest quarterly gains on record. This positive sentiment is further boosted by the possibility of marijuana being reclassified from a Schedule I substance, which could reduce the burden on cannabis companies.
The reclassification of marijuana could pave the way for more cannabis companies to list on U.S. stock exchanges, attracting interest from institutional investors. It could also represent a first step towards aligning state and federal cannabis laws. However, it is important to note that marijuana remains listed as a Schedule I substance, and the reclassification process is still ongoing. As of October 2025, there is no final decision from the U.S. government on this matter.
